The Journal of Urology
Volume 182, Issue 5 , Pages 2109-2111 , November 2009

Should Testosterone Replacement be Given to Men With Large Prostates?

  • Leonard S. Marks

      Affiliations

    • Urological Sciences Research Foundation, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
    • ,
  • Steven A. Kaplan

      Affiliations

    • Institute for Bladder and Prostate Health, Weill Cornell Medical College, Cornell Medical College, New York, New York

References 

  1. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351
  2. Marberger M, Roehrborn CG, Marks LS, et al. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:1323
  3. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170
  4. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482
  5. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008;72:247
  6. Morris MJ, Huang D, Kelly WK, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009;
  7. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310
  8. AUA guideline on management of benign prostatic hyperplasia (2003) (Chapter 1: diagnosis and treatment recommendations). J Urol. 2003;170:530
  9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  10. GSK press release: Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10047.htm
  11. Kaplan SA, Roehrborn CG, Meehan AG, et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology. 2009;73:935

PII: S0022-5347(09)02166-1

doi: 10.1016/j.juro.2009.08.101

The Journal of Urology
Volume 182, Issue 5 , Pages 2109-2111 , November 2009

Article Tools